Unglycosylated Soluble SARS-CoV-2 Receptor Binding Domain (RBD) Produced in <i>E. coli</i> Combined with the Army Liposomal Formulation Containing QS21 (ALFQ) Elicits Neutralizing Antibodies against Mismatched Variants

The emergence of novel potentially pandemic pathogens necessitates the rapid manufacture and deployment of effective, stable, and locally manufacturable vaccines on a global scale. In this study, the ability of the <i>Escherichia coli</i> expression system to produce the receptor binding...

Full description

Bibliographic Details

Published in:	Vaccines
Main Authors:	Arasu Balasubramaniyam, Emma Ryan, Dallas Brown, Therwa Hamza, William Harrison, Michael Gan, Rajeshwer S. Sankhala, Wei-Hung Chen, Elizabeth J. Martinez, Jaime L. Jensen, Vincent Dussupt, Letzibeth Mendez-Rivera, Sandra Mayer, Jocelyn King, Nelson L. Michael, Jason Regules, Shelly Krebs, Mangala Rao, Gary R. Matyas, M. Gordon Joyce, Adrian H. Batchelor, Gregory D. Gromowski, Sheetij Dutta
Format:	Article
Language:	English
Published:	MDPI AG 2022-12-01
Subjects:	vaccine recombinant <i>E. coli</i> SARS-CoV-2 RBD
Online Access:	https://www.mdpi.com/2076-393X/11/1/42